Immunotherapy for pancreatic cancer: A 2020 update
Pancreatic adenocarcinoma (PAC) is the seventh leading cause of cancer-related death in both sexes, causing more than 331,000 deaths per year globally [1]. An estimation of 174,650 new cases was expected to be diagnosed in the USA with 45,750 deaths expected to occur in 2019 [2]. PAC is associated with an extremely poor prognosis reaching a 5-year overall survival (OS) rate below 5% [3] and 1-year OS rate at 24% based on standard treatments [4]. Even for patients with resectable disease, the prognosis is very poor, reflecting an OS rate of only 17% [4].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Dimitrios Schizas, Nikolaos Charalampakis, Christo Kole, Panagiota Economopoulou, Evangelos Koustas, Efthymios Gkotsis, Dimitrios Ziogas, Amanda Psyrri, Michalis V. Karamouzis Tags: Hot Topic Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Immunotherapy | Pancreas | Pancreatic Cancer